About Multus
Multus is a company based in London (United Kingdom) founded in 2019 by Kevin Pan, Cai Linton, and Reka Tron. Multus has raised $9.3 million across 5 funding rounds from investors including UK Research and Innovation, European Union and Asahi Kasei. The company has 8 employees. Multus operates in a competitive market with competitors including BioLife Solutions, RoosterBio, Shanghai Doning Biotechnology, ArunA Bio and Biotangents, among others.
- Headquarter London, United Kingdom
- Employees 8
- Founders Kevin Pan, Cai Linton, Reka Tron
- SectorsHealthcare
- Email••••••••
- Website multus.bio
- Social LinkedIn X
- Legal Name Multus Biotechnology Limited
- Date of Incorporation 18 Mar, 2020
- Jurisdiction LONDON, UNITED KINGDOM
- Total Equity Funding$9.3M (USD)
in 5 rounds
- Latest Funding Round$7M (USD), Series A
Jan 2023
- InvestorsUK Research and Innovation
& 10 more
- Employee Count8
Funding Insights of Multus
Multus has successfully raised a total of $9.3M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $7 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.3M
- Total Rounds 5
- Last Round Series A — $7M
- First Round $250,000
(Jun 2020)
- Investors Count 11
All 5 funding rounds of Multus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $2.5M | Grant | – | – | |
| Jan 2023 | $7M | Series A | – | Mandi Ventures, SOSV | |
| Jul 2021 | $146,000 | Grant | – | – | |
| Jul 2021 | $2.05M | Seed | – | SOSV, Marinya Capital | |
| Jun 2020 | $250,000 | Seed | – | IndieBio | – |
11 investors in total: 10 institutional and 1 angel.
Investors in Multus
Multus has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include UK Research and Innovation, European Union and Asahi Kasei.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in tech-enabled food chain sustainability startups. | – | mandiventures.com | Paris, France | |
Venture capital and accelerator services are provided across multiple sectors. | – | sosv.com | Cork, Ireland | |
Investments are directed toward plant-based food innovations and technologies. | – | bigideaventures.com | New York, United States | |
- | – | synbioven.com | - | |
- | – | marinyacapital.tcc.mode | - | |
- | – | zerocarbon.vc | - | |
Biotech startups are accelerated through IndieBio's focused programs. | – | indiebio.co | San Francisco, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
CDMO focused on manufacturing of liquid, solid & injectable drug formulations | 1931 | asahi-kasei.com | Tokyo, Japan | |
Research and innovation funding is managed for UK advancement. | 2018 | ukri.org | Swindon, United Kingdom |
Investor details for Multus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Multus
20 people are tracked at Multus (6 in leadership, 5 in board & advisors, 9 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Kevin Pan | Co-Founder & CTO | Leadership |
Cai Linton | Co-Founder & CEO | Leadership |
Reka Tron | Co-Founder & COO | Leadership |
Charlie Taylor | Head of Business Development | Leadership |
Anirvan Guha | Head of Formulations | Leadership |
George Taylor | Head of Ingredients | Leadership |
Matt Tom | Advisor | Board & advisors |
Jonathan Lydiard-Wilson | Advisor | Board & advisors |
Michael Butler | Advisor | Board & advisors |
Frank Klemens | Advisor | Board & advisors |
Molly Stevens | Advisor | Board & advisors |
Sandesh Meyler | Research Scientist | Team |
Ioanna Bechlivanidi | Laboratory Manager | Team |
Cristina Guzman-Moumtzis | Research Scientist | Team |
Nchimunya Nelisa Tebeka | Research Scientist | Team |
Soraya Padilla Lopategui | Subgroup Lead of Formulations | Team |
Anthony Cheuk | Research Scientist | Team |
Jake Bell | Research Scientist | Team |
Seong Hyun Ma | Research Scientist | Team |
Julian Arjuna Bisten | Production Scientist | Team |
Complete people profiles for Multus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Multus
3 dated milestones of Multus across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Multus is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series A, of $7.0M.
Competitors of Multus
Multus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, RoosterBio, Shanghai Doning Biotechnology, ArunA Bio and Biotangents, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| duoningbio.com | 2005 | Shanghai, China | $14.88M | – | Serum-free cell culture media is supplied to biopharmaceutical industries. | |
| arunabio.com | 2017 | Athens, United States | $38.51M | – | Neural exosome platform is developed for neurodegenerative disease therapeutics. | |
| biotangents.co.uk | 2015 | Edinburgh, United Kingdom | $5.62M | 13 | Veterinary diagnostics products are developed for bovine viral diarrhea testing. | |
| fabricnano.com | 2018 | London, United Kingdom | $22.6M | 12 | DNA-based flow reactors are developed for biochemical production. | |
| polyplus-transfection.com | 2001 | Illkirch Graffenstaden, France | $3.23M | – | Transfection Solutions for Healthcare and Life Sciences organizations | |
| idtdna.com | 1987 | Coralville, United States | – | – | Provider of oligonucleotide-based reagents and kits | |
| pl-bioscience.com | 2015 | Aachen, Germany | $13.03M | 13 | Cell culture solutions for stem cell expansion are provided. | |
| biolamina.com | 2008 | Sundbyberg, Sweden | $18.25M | – | Recombinant laminins are produced for stem cell culture matrices. |
Detailed competitors of Multus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Multus
Websites that share an audience with Multus (multus.bio).
Websites whose visitors overlap most with Multus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lbic.com | 100% | – | #4,573,435 | View details | |
| insightbio.com | 98% | 5K | #3,682,821 | View details | |
| dnanudge.com | 95% | – | – | View details | |
| ellipses.life | 90% | 4.3K | #4,843,780 | View details | |
| touchlight.com | 89% | 6.3K | #4,432,265 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Multus
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Multus
Complete news archive for Multus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Multus
10 companies that operate in the same segment as Multus (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Multus
Multus was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Multus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Cai Linton is the current CEO of Multus. They have also founded this company.
Multus is a funded company, having raised a total of $9.3M across 5 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Jun 2020.
Multus has 8 employees.
Provider of lab-grown meat alternatives. The company claims it is using cells from livestock animals and multiplying them in the laboratory to obtain whole cuts of meat.
Multus's top competitors include FabricNano, RoosterBio and BioLife Solutions.
Multus has 11 investors. Key investors include UK Research and Innovation, European Union, Asahi Kasei, Mandi Ventures, and SOSV.
Multus operates through Multus Biotechnology Limited.